| Update on TS clinical trial plans | |
| Study design trials and tribulations | Dr. Dan Sargent Dr. Richard Schilsky |
| Discussion — Potential problems in designing marker-guided trials | |
| Development of agents that target EGFR and related signaling pathway components | |
| EGFR and cell signaling — What we know and the agents in the pipeline |
Dr. Janet Dancey |
| EGFR assay development | Dr. Barbara Conley |
| General discussion of EGFR and the laboratory assay issues associated with development of molecular targets | |
| Tissue micro-arrays and their use in the clinical laboratory | |
| How will molecular signatures/profiles be translated to the clinic? | |
| Progress report from the Director’s Challenge and related research | Dr. James Jacobson |
| Discussion: What are the likely clinical uses of signature/profile information? Will the ongoing research move toward these uses? What other studies will be needed? What resources will be needed? |
